Roche's Q1 Sales Surge

F. Hoffmann-La Roche AG announced a robust start to fiscal 2025, with first-quarter sales reaching 15.4 billion Swiss francs. This marks a 7% increase in Swiss francs and a 6% rise at constant exchange rates (CER) compared to the previous year.

Division Highlights

The pharmaceuticals division saw an 8% growth at CER, totaling 11.95 billion Swiss francs. Meanwhile, the diagnostics division maintained steady performance with sales of 3.49 billion Swiss francs, mirroring last year's figures.

CEO's Vision

"We had a good start to the year," stated CEO Thomas Schinecker, highlighting the company's 6% CER sales growth. He also announced a significant $50 billion investment to expand Roche's US presence, aiming to meet patient needs with innovative medicines and diagnostics.